This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ZELTIQ® Aesthetics Preliminary Injunction Against Clinipro In Spain Still On Record And In Full Force

ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that the preliminary injunction originally granted by the Mercantile Court in Spain on May 4, 2012, still stands despite recent reports from Clinipro that it has been suspended.

The lawsuit against Clinipro in Spain alleges infringement of two European patents owned by Massachusetts General Hospital (MGH) and licensed exclusively to ZELTIQ. After hearing the petition for a preliminary injunction on May 4, the Mercantile Court in Spain granted ZELTIQ’s and MGH’s request thereby prohibiting Clinipro’s further importation, manufacture, distribution, offering for sale and sale of Clinipro’s LipoCryo device in Spain. The Mercantile Court subsequently scheduled a trial on the merits for a permanent injunction against Clinipro’s LipoCryo device to be held on September 18, 2012. While Clinipro has petitioned the Mercantile Court to suspend the preliminary injunction order, the Court determined that a suspension would not be granted unless Clinipro deposits the sum of €50,000 euros each month until the September trial in the case to cover ZELTIQ’s damages resulting from Clinipro’s ongoing patent infringement. As Clinipro has not deposited any funds, the preliminary injunction has not been, and cannot be suspended.

As a result, and under the existing Mercantile Court order, Clinipro is still banned from importation, manufacture, distribution, offering for sale and sale of Clinipro’s LipoCryo device in Spain. To continue to do so, as the company willingly acknowledged in its press release issued on July 3, 2012, only serves as an admission by Clinipro that it has been violating the Mercantile Court’s May 4 preliminary injunction order.

Mark Foley, interim President and Chief Executive Officer of ZELTIQ, commented, “It is unfortunate that Clinipro chose to publically issue a misleading statement and build on a campaign of market confusion. As a company, ZELTIQ is steadfast in its commitment to defend its intellectual property rights. We are confident that the Mercantile Court in Spain will again rule in our favor at the September trial as already demonstrated by the May 4 preliminary injunction order, and by the Court’s recent rejection of Clinipro’s petition to suspend the injunction without first depositing significant sums to cover ZELTIQ’s damages as a result of Clinipro’s ongoing patent infringement.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs